Literature DB >> 17310988

cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis.

D Wu1, H E Zhau, W-C Huang, S Iqbal, F K Habib, O Sartor, L Cvitanovic, F F Marshall, Z Xu, L W K Chung.   

Abstract

Aberrant expression of vascular endothelial growth factor (VEGF) is associated with human prostate cancer (PCa) metastasis and poor clinical outcome. We found that both phosphorylation of cyclic AMP-responsive element-binding protein (CREB) and VEGF levels were significantly elevated in patient bone metastatic PCa specimens. A PCa ARCaP progression model demonstrating epithelial-to-mesenchymal transition exhibited increased CREB phosphorylation and VEGF expression as ARCaP cells became progressively more mesenchymal and bone-metastatic. Activation of CREB induced, whereas inhibition of CREB blocked, VEGF expression in ARCaP cells. CREB may regulate VEGF transcription via a hypoxia-inducible factor-dependent mechanism in normoxic conditions. Activation of CREB signaling is involved in the coordinated regulation of VEGF and may pre-dispose to PCa bone metastasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17310988     DOI: 10.1038/sj.onc.1210316

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  71 in total

1.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Authors:  Gary E Gallick; Paul G Corn; Amado J Zurita; Sue-Hwa Lin
Journal:  Future Med Chem       Date:  2012-01       Impact factor: 3.808

2.  Targeting CREB for cancer therapy: friend or foe.

Authors:  Xiangshu Xiao; Bingbing X Li; Bryan Mitton; Alan Ikeda; Kathleen M Sakamoto
Journal:  Curr Cancer Drug Targets       Date:  2010-06       Impact factor: 3.428

3.  Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells.

Authors:  Shumin Zhang; Yanru Wang; Zhengjia Chen; Sungjin Kim; Shareen Iqbal; Andrew Chi; Chad Ritenour; Yongqiang A Wang; Omer Kucuk; Daqing Wu
Journal:  Prostate       Date:  2013-09-02       Impact factor: 4.104

4.  β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells.

Authors:  Sajni Josson; Takeo Nomura; Jen-Tai Lin; Wen-Chin Huang; Daqing Wu; Haiyen E Zhau; Majd Zayzafoon; M Neale Weizmann; Murali Gururajan; Leland W K Chung
Journal:  Cancer Res       Date:  2011-03-22       Impact factor: 12.701

5.  Changes in vascular endothelial growth factor (VEGF) induced by the Morris water maze task.

Authors:  Dong Hoon Oh; Byung Woo Kim; Miyeon Choi; Garim Lee; June-Seek Choi
Journal:  Mol Cells       Date:  2012-03       Impact factor: 5.034

6.  Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry.

Authors:  Prodipto Pal; Huifeng Xi; Saurav Guha; Guangyun Sun; Brian T Helfand; Joshua J Meeks; Brian K Suarez; William J Catalona; Ranjan Deka
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

Review 7.  Understanding the CREB1-miRNA feedback loop in human malignancies.

Authors:  Ya-Wen Wang; Xu Chen; Rong Ma; Peng Gao
Journal:  Tumour Biol       Date:  2016-04-09

Review 8.  Transcriptional switches: chemical approaches to gene regulation.

Authors:  Lori W Lee; Anna K Mapp
Journal:  J Biol Chem       Date:  2010-02-10       Impact factor: 5.157

9.  Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer.

Authors:  Yang Yang; Kenza Mamouni; Xin Li; Yanhua Chen; Sravan Kavuri; Yuhong Du; Haian Fu; Omer Kucuk; Daqing Wu
Journal:  Mol Cancer Ther       Date:  2018-06-15       Impact factor: 6.261

10.  Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.

Authors:  Shumin Zhang; Haiyen E Zhau; Adeboye O Osunkoya; Shareen Iqbal; Xiaojian Yang; Songqing Fan; Zhengjia Chen; Ruoxiang Wang; Fray F Marshall; Leland W K Chung; Daqing Wu
Journal:  Mol Cancer       Date:  2010-01-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.